Atlas Trials

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Clinical trial NCT04943198 · RECRUITING

Trial details

NCT number
NCT04943198
Sponsor
Anna Raciborska
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Histiocytosis
Start date
2021-04-01
Primary completion
2027-06-30
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.